Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Clinical Trials

18 clinical trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 — RECRUITING · PHASE1
• A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) — RECRUITING · PHASE1
• A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) — RECRUITING · PHASE1
• A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. — NOT_YET_RECRUITING · PHASE1
• A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) — ACTIVE_NOT_RECRUITING · PHASE1
• Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma — NOT_YET_RECRUITING
• Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma — TERMINATED · PHASE1
• Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) — TERMINATED · PHASE1
• Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — NOT_YET_RECRUITING · NA
• Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) — OTHER · PHASE2
• CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies — OTHER · PHASE1
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — OTHER · NA
• Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) — OTHER · PHASE1
• Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia — OTHER · PHASE1
• Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes — OTHER · PHASE1

Refine this search